Background: B-type natriuretic peptide (BNP) and its N-terminal portion (NT-pro-BNP) are used for the assessment of cardiac dysfunction in patients with heart failure. However, it remains controversial whether or not this option is still valid in critically ill patients because of a possible interaction between the systemic inflammatory response and the natriuretic peptide levels. The aim of this study was to assess the relationship between natriuretic peptic levels, laboratory parameters of systemic inflammation, and pulmonary artery occlusion pressure (PAOP) in critically patients.
Methods: Twelve haemodyamic unstable patients, all monitored with a pulmonary artery catheter, were included in this study. Subgroups were compared using measurement values on ICU admission. Within patient associations between different variables were evaluated by a repeated measurement ancova.
Results: Acute heart failure and septic shock were diagnosed in 6 patients each. Despite significant differences in cardiac index and troponin T plasma level, BNP and NT-pro-BNP levels did not differ significantly between the two groups. Within patient, changes in BNP and NT-pro-BNP levels correlated significantly (p<0.01) with those in C-reactive protein values and those in leukocyte counts, but did not follow changes in PAOP.
Conclusion: Our results add further evidence to the hypothesis that there is an interaction between the systemic inflammatory response and the natriuretic peptides. Thus, BNP and NT-pro-BNP levels should only be used cautiously as surrogates of cardiac filling and function in haemodynamic unstable critically ill patients.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.ijcard.2007.03.108 | DOI Listing |
Viruses
December 2024
Faculty of Medicine, Federal University of Vale do São Francisco-UNIVASF, Petrolina 56304-917, PE, Brazil.
Arthropod-borne viral diseases are acute febrile illnesses, sometimes with chronic effects, that can be debilitating and even fatal worldwide, affecting particularly vulnerable populations. Indigenous communities face not only the burden of these acute febrile illnesses, but also the cardiovascular complications that are worsened by urbanization. A cross-sectional study was conducted in an Indigenous population in the Northeast Region of Brazil to explore the association between arboviral infections (dengue, chikungunya, and Zika) and cardiac biomarkers, including cardiotrophin 1, growth differentiation factor 15, lactate dehydrogenase B, fatty-acid-binding protein 3, myoglobin, N-terminal pro-B-type natriuretic peptide, cardiac troponin I, big endothelin 1, and creatine kinase-MB, along with clinical and anthropometric factors.
View Article and Find Full Text PDFMicroorganisms
December 2024
Department of Internal Medicine II, Medical University of Innsbruck, Anichstraße 35, 6020 Innsbruck, Austria.
Coronavirus Disease 2019 causes significant morbidity, and different variants of concern (VOCs) can impact organ systems differently. We conducted a single-center retrospective cohort analysis comparing biomarkers and clinical outcomes in hospitalized patients infected with the wild-type or Alpha (wt/Alpha) VOC against patients infected with the Omicron VOC. We included 428 patients infected with the wt/Alpha VOC and 117 patients infected with the Omicron VOC.
View Article and Find Full Text PDFMedicina (Kaunas)
November 2024
Department of Microbiology, "Victor Babes" University of Medicine and Pharmacy, 300041 Timisoara, Romania.
: Heart failure is associated with high morbidity and mortality and linked with several pre-existing health conditions and risk factors. Early detection and prompt management in heart failure improves patient outcomes. Liver involvement is associated with heart failure disease progression, and hence liver biomarkers and liver fibrosis may have a prognostic impact.
View Article and Find Full Text PDFJ Clin Med
December 2024
School of Medicine, College of Medicine Nursing and Health Sciences, University of Galway, H91 TK33 Galway, Ireland.
Sacubitril/valsartan is an angiotensin receptor-neprilysin inhibitor (ARNI) drug used to treat patients with heart failure and has shown improvement in outcomes. Different studies reported the use of an ARNI in patients using left ventricular assist devices (LVADs). However, there are limited data on the use of ARNIs in this population.
View Article and Find Full Text PDFJ Clin Med
December 2024
Second Department of Internal Medicine, University of Toyama, Toyama 930-8555, Japan.
Hypoxia-inducible factor-prolyl hydroxylase (HIF-PH) inhibitors have been developed as a treatment for renal anemia. However, their therapeutic impact on patients with concomitant heart failure remains uncertain. We investigated the impact of HIF-PH inhibitors on improving renal anemia and associated clinical outcomes in patients with heart failure.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!